The MNT Knockout Raji Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the Raji human B lymphocyte cell line. These cells carry a targeted disruption of the MNT gene, which encodes a MAX-interacting transcriptional repressor. By ablating MNT function, the cells enable investigation of MYC/MNT transcriptional balance in a B-cell lymphoma context. The polyclonal nature of the knockout pool ensures representation of diverse editing events while maintaining a consistent loss-of-function phenotype suitable for population-level analyses.
The Raji cell line is an Epstein-Barr virus (EBV)-positive human Burkitt’s lymphoma line widely used as a model for B-cell lymphomagenesis and immune research. These B lymphocytes harbor a constitutively active MYC oncogene due to chromosomal translocation, providing a hyperproliferative background that underscores the centrality of MYC network deregulation in lymphomagenesis. Raji cells are characterized by their rapid growth, expression of B-cell surface markers, and susceptibility to EBV-driven transformation pathways, making them an ideal host for studying transcriptional and signaling mechanisms in B-cell malignancies.
MNT functions as a critical antagonist of MYC-dependent transcription. It heterodimerizes with MAX and binds E-box DNA sequences, subsequently recruiting the SIN3A/HDAC co?repressor complex containing HDAC1 and HDAC2. This complex deacetylates histones and silences genes involved in cell cycle progression and apoptosis, including CDKN1A, BCL2, and ODC1. MNT activity is modulated by upstream signals such as PI3K/AKT-mediated phosphorylation and CDK-dependent mechanisms, and it operates in direct competition with MYC for MAX heterodimerization, thereby serving as a key rheostat in the oncogenic MYC signaling network.
In the Raji Burkitt’s lymphoma line, loss of MNT removes a crucial brake on MYC transcriptional output, potentially amplifying oncogenic programs driven by the endogenous MYC translocation and EBV latency factors. The EBV?positive background is particularly relevant because viral proteins modulate MYC expression and activity, and the interplay between MNT and EBV-driven signaling pathways remains an underexplored area. This knockout model therefore offers a unique system to dissect how loss of MNT-mediated repression cooperates with pre-existing oncogenic lesions to promote B-cell lymphomagenesis.
Researchers can employ Western blotting, RT?qPCR, RNA?seq, and ChIP?qPCR to quantify MNT and E?box target gene changes and occupancy. Co?immunoprecipitation reveals MAX interaction dynamics, while flow cytometry enables proliferation and apoptosis profiling. Drug sensitivity assays with MYC pathway inhibitors help identify synthetic lethal dependencies. These polyclonal knockout cells thus offer a versatile platform for mechanistic dissection and preclinical drug discovery in MYC?driven B?cell malignancies. For technical inquiries and support, please contact Ascent Research.
